Codexis' ECO Synthesis® Manufacturing Platform: Transforming RNA Therapeutics [CBS News]
Codexis, Inc. (CDXS)
Last codexis, inc. earnings: 2/27 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.codexis.com/investors
Company Research
Source: CBS News
RNA-based medicines are transforming the way we treat disease—offering targeted, precision therapies for conditions ranging from rare genetic disorders to widespread chronic illnesses like diabetes, cardiovascular disease, and cancer. But as the potential of RNA therapeutics expands, so does the challenge of producing them at scale and in a sustainable manner. Solid-phase oligonucleotide synthesis (SPOS), while foundational to early RNA therapeutics development, is increasingly unsuited for the demands of commercial manufacturing. This process is complex, resource-intensive, and environmentally burdensome—relying on hazardous reagents and generating significant waste. As a result, the industry faces a critical bottleneck: the research fueling RNA therapies is advancing rapidly, but manufacturing capabilities are struggling to keep pace. Codexis is solving this problem with its ECO Synthesis® Manufacturing Platform—a breakthrough enzymatic approach to therapeutic RNA production. B
Show less
Read more
Impact Snapshot
Event Time:
CDXS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CDXS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CDXS alerts
High impacting Codexis, Inc. news events
Weekly update
A roundup of the hottest topics
CDXS
News
- Sonoma Biotherapeutics Announces Transition of Jeff Bluestone, PhD, to Advisor; Appoints Stephen Dilly, MBBS, PhD, as President and Chief Executive Officer [Yahoo! Finance]Yahoo! Finance
- Codexis Announces Signing of Lease for GMP Manufacturing Facility [Yahoo! Finance]Yahoo! Finance
- Codexis Announces Signing of Lease for GMP Manufacturing FacilityGlobeNewswire
- Codexis (NASDAQ:CDXS) was downgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=CDXS&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> MarketBeat
- Codexis Reports Third Quarter 2025 Financial ResultsGlobeNewswire
CDXS
Earnings
- 11/6/25 - Miss
CDXS
Sec Filings
- 12/1/25 - Form 4
- 11/25/25 - Form 4
- 11/21/25 - Form 144
- CDXS's page on the SEC website